Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606122 | 0.93 | CTSB (0.43) | CTSKCTSSCTSLCTSBANPEP | |
| SCHEMBL7639995 | 0.87 | CTSK (0.43) | CTSKCTSSCTSLCTSBSLC15A1 | |
| SCHEMBL7420644 | 0.82 | ANPEP (0.43) | CTSKCTSSCTSLCTSBANPEP | |
| SCHEMBL7375434 | 0.82 | CTSK (0.64) | CTSKCTSSCTSLCTSB | |
| SCHEMBL1014662 | 0.81 | CTSB (0.44) | CTSKCTSSCTSLCTSBANPEP | |
| SCHEMBL27809385 | 0.81 | ANPEP (0.48) | CTSKCTSSCTSLCTSBANPEP | |
| SCHEMBL7607048 | 0.81 | ABCB1 (0.41) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL7466824 | 0.80 | CTSK (0.49) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL27473269 | 0.80 | ANPEP (0.45) | CTSKCTSSCTSLCTSBANPEP | |
| SCHEMBL27799677 | 0.80 | ANPEP (0.45) | CTSKCTSSCTSLCTSBANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467144-A1 | COMBINATION OF PROTEASOME INHIBITORS AND ANTI-HEPATITIS MEDICATION FOR TREATING HEPATITIS | ViroLogik GmbH (DE) | 2012-06-27 | — | — | EP | claimed |
| WO-2011009961-A1 | COMBINATION OF PROTEASOME INHIBITORS AND ANTI-HEPATITIS MEDICATION FOR TREATING HEPATITIS | VIROLOGIK GMBH (DE) | 2011-01-27 | — | — | WO | claimed |
| EP-2078201-A2 | DENGUE DIAGNOSIS AND TREATMENT | Agency for Science, Technology and Research (SG) | 2009-07-15 | — | — | EP | claimed |
| WO-2008041953-A2 | DENGUE DIAGNOSIS AND TREATMENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-04-10 | — | — | WO | claimed |
| EP-0040435-B1 | PEPTIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Eisai Co., Ltd. (JP) | 1983-07-20 | — | — | EP | claimed |
| EP-0040435-A1 | Peptide derivatives and process for the preparation thereof | Eisai Co., Ltd. (JP) | 1981-11-25 | — | — | EP | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20190010449-A1 | Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-01-10 | — | — | US | disclosed |
| WO-2015104292-A2 | COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2015-07-16 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| EP-2608811-A1 | ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF STIMULATING AN IMMUNE RESPONSE USING SAID BIOCONJUGATES | Providence Health System - Oregon (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2009067543-A2 | TREATMENT OF HISTONE DEACETYLASE MEDIATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1382691-B1 | Method for the isolation of the 20S proteasome, and methods for the identification of 20S and 26S proteasome inhibitors | BAYER CROPSCIENCE AG (DE) | 2006-10-18 | — | — | EP | disclosed |
| EP-1492545-A1 | AGENTS FOR TREATING I FLAVIVIRIDAE /I INFECTIONS | VIROMICS GMBH (DE) | 2005-01-05 | — | — | EP | disclosed |
| EP-1382691-A2 | Method for the isolation of the 20S proteasome, and methods for the identification of 20S and 26S proteasome inhibitors | Bayer CropScience AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003084551-A1 | AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS | VIROMICS GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-0040435-B1 | PEPTIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Eisai Co., Ltd. (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0040435-A1 | Peptide derivatives and process for the preparation thereof | Eisai Co., Ltd. (JP) | 1981-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | CTSK 357/4885CTSS 661/4885CTSL 1583/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | CTSK 357/4885CTSS 661/4885CTSL 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.